Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYFORM-008: favezelimab + pembrolizumab versus physician's choice chemotherapy in PD-(L)1-refractory relapsed or refractory classical Hodgkin lymphoma
2022-000371-39Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of favezelimab, pembrolizumab, bendamustine and gemcitabine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival. Started Jun 2022; status: active.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-000371-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000371-39.